We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




New Antimicrobial Wound Dressing

By HospiMedica staff writers
Posted on 02 Apr 2003
A new wound dressing has been proven effective in vitro against more than 150 clinically relevant wound pathogens, including antibiotic-resistant strains such as Staphylococcus aureus and vancomycin-resistant Enterococcus.

Called Actisorb Silver 220, the dressing is the product of Johnson & Johnson Wound Management (New Brunswick, NJ, USA). More...
The company states that in a recent article in the Journal of Hospital Infections (2003;53:211-214), it was concluded that the dressing may be beneficial in the treatment of infected wounds, particularly when colonized by Gram-negative bacteria. The dressing demonstrated a high in vitro endotoxin-binding capacity combined with marked bactericidal activity without releasing Pseudomonas aeruginosa endotoxins into the environment.

The dressing combines broad-spectrum antimicrobial action with bacterial toxin management and odor control. In a clinical study of more than 12,400 chronic wounds, the dressing proved safe and effective. It is suitable for use under compression bandaging and may help reduce infection in partial- and full-thickness wounds, including surgical wounds, donor sites, second-degree burns, diabetic ulcers, venous ulcers, and pressure ulcers. Because the dressing contains silver, it should not be used on patients with known sensitivity to silver. Also, it should not be used on third-degree burns.





Related Links:
Johnson & Johnson

Gold Member
STI Test
Vivalytic Sexually Transmitted Infection (STI) Array
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Neonatal Ventilator Simulation Device
Disposable Infant Test Lung
Mammo DR Retrofit Solution
DR Retrofit Mammography
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.